Decoding the immune system.

About

Late detection is the key problem of immune-related diseases.

• Cancer

  Most cancers are detected in late stages.

  But tumours elicit an immune response before cancer cells themselves are detectable in blood.

• Immune-mediated inflammatory diseases

  With no prognosis available, treatment regimes equal trial and error.

  But immune signatures can predict the severity of immune-related diseases and point to the right therapy at the time of diagnosis.

Using the immune system to detect diseases earlier.

• 

  Beyond biomarkers.

  Deciphering subtle, complex and individual immune interactions.

• 

  Ultra-sensitive.

  Our AI technology can detect immune signatures missed by human analysis.

• 

  Scalable.

  Our technology is blood-based and applicable to standard clinical infrastructure.

Team

• 

  Julia Stachowiak

  Co-founder & CEO

  Julia is a medical doctor and chemist.

  She gained in-depth business development expertise during the AI Founder Fellowship (AIFF) and has strong clinical and research experience in immuno-oncology and gastroenterology. She established key clinical partnerships for decyte and leads both clinical validation and go-to-market strategy.

• 

  Hanna Roetschke, PhD

  Co-founder & CTO

  Operating at the intersection of biomedicine and data science, Hanna has established a track record in cutting-edge immuno-oncology research, and created a platform for interdisciplinary scientists. Building on that experience, she is now developing a fundamentally new approach for disease detection at decyte.

  Hanna earned her PhD from King’s College London and the Francis Crick Institute as one of the youngest graduates in the university’s history.

Contact

We'd love to hear from you!

Get in touch via email or LinkedIn if you want to know more about what we are building.